Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Translating Germline Cancer Risk into Precision Prevention.

Yurgelun MB, Chenevix-Trench G, Lippman SM.

Cell. 2017 Feb 9;168(4):566-570. doi: 10.1016/j.cell.2017.01.031.

2.

Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM.

Cancer Prev Res (Phila). 2016 Jan;9(1):2-10. doi: 10.1158/1940-6207.CAPR-15-0406.

3.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

4.

Germline mutations in lung cancer and personalized medicine.

Cetta F, Renieri A, Frullanti E.

Fam Cancer. 2018 Jul;17(3):429-430. doi: 10.1007/s10689-017-0044-4. No abstract available.

PMID:
28914390
5.

Cancer molecular markers: A guide to cancer detection and management.

Nair M, Sandhu SS, Sharma AK.

Semin Cancer Biol. 2018 Oct;52(Pt 1):39-55. doi: 10.1016/j.semcancer.2018.02.002. Epub 2018 Feb 8. Review.

PMID:
29428478
6.

Cancer predisposition syndromes: lessons for truly precision medicine.

Glaire MA, Brown M, Church DN, Tomlinson I.

J Pathol. 2017 Jan;241(2):226-235. doi: 10.1002/path.4842. Epub 2016 Nov 30. Review.

PMID:
27859368
7.

[Genomics medicine and oncology].

Michielin O, Coukos G.

Praxis (Bern 1994). 2014 May 7;103(10):591-6. doi: 10.1024/1661-8157/a001659. French.

PMID:
24800772
8.

Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine.

Powers B, Pal T, Laronga C.

Surg Oncol Clin N Am. 2018 Jan;27(1):1-22. doi: 10.1016/j.soc.2017.08.003. Review.

PMID:
29132555
9.

Public health genomics and personalized prevention: lessons from the COGS project.

Pashayan N, Hall A, Chowdhury S, Dent T, Pharoah PD, Burton H.

J Intern Med. 2013 Nov;274(5):451-6. doi: 10.1111/joim.12094.

10.

Integrating germline and somatic data towards a personalized cancer medicine.

Pujana MA.

Trends Mol Med. 2014 Aug;20(8):413-5. doi: 10.1016/j.molmed.2014.05.004.

PMID:
25086750
11.

Therapeutic implications of germline genetic findings in cancer.

Thavaneswaran S, Rath E, Tucker K, Joshua AM, Hess D, Pinese M, Ballinger ML, Thomas DM.

Nat Rev Clin Oncol. 2019 Jun;16(6):386-396. doi: 10.1038/s41571-019-0179-3. Review. Erratum in: Nat Rev Clin Oncol. 2019 Apr 17;:.

PMID:
30783251
12.

Future of personalized medicine in oncology: a systems biology approach.

Gonzalez-Angulo AM, Hennessy BT, Mills GB.

J Clin Oncol. 2010 Jun 1;28(16):2777-83. doi: 10.1200/JCO.2009.27.0777. Epub 2010 Apr 20. Review.

13.

Cancer genomics and inherited risk.

Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K.

J Clin Oncol. 2014 Mar 1;32(7):687-98. doi: 10.1200/JCO.2013.49.7271. Epub 2014 Jan 21.

14.

[Management of hereditary ovarian cancer].

Joó JG, Ládi S, Nagy BZ, Langmár Z.

Orv Hetil. 2011 Oct 2;152(40):1596-608. doi: 10.1556/OH.2011.29218. Review. Hungarian.

PMID:
21945869
15.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
16.

Personalized genomic analyses for cancer mutation discovery and interpretation.

Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, Galens KG, Murphy D, Zhang T, Kann L, Sausen M, Angiuoli SV, Diaz LA Jr, Velculescu VE.

Sci Transl Med. 2015 Apr 15;7(283):283ra53. doi: 10.1126/scitranslmed.aaa7161.

17.

The evidence for expanded genetic testing for pediatric patients with cancer.

Maese L, Schiffman JD.

Future Oncol. 2018 Feb;14(3):187-190. doi: 10.2217/fon-2017-0467. Epub 2018 Jan 12. No abstract available.

18.

Precision Oncology: Are We There Yet?

[No authors listed]

EBioMedicine. 2017 Apr;18:1-2. doi: 10.1016/j.ebiom.2017.04.023. No abstract available.

19.

Delivering on the promise of precision cancer medicine.

Berger MF, Van Allen EM.

Genome Med. 2016 Oct 25;8(1):110. No abstract available.

20.

Genetic testing by cancer site: stomach.

Chun N, Ford JM.

Cancer J. 2012 Jul-Aug;18(4):355-63. doi: 10.1097/PPO.0b013e31826246dc. Review.

PMID:
22846738

Supplemental Content

Support Center